Dose Escalation

Dose Escalation refers to the controlled increase of administered dose levels in clinical trials to identify safe and tolerable exposure ranges while characterising pharmacokinetics, pharmacodynamics, and early efficacy signals. This approach is common in first-in-human studies, oncology development, and novel modality trials where optimal dosing is uncertain. Dose escalation designs include traditional 3+3 schemes, accelerated titration methods, and model-based designs such as Bayesian approaches that improve efficiency and safety.

The pharmaceutical industry uses dose escalation to establish recommended phase II doses while minimising risk to participants. Safety monitoring includes adverse event tracking, laboratory assessments, and predefined stopping rules triggered by dose-limiting toxicities. Biomarkers and target engagement data increasingly guide escalation decisions, enabling more rational dose selection beyond maximum tolerated dose concepts. Regulatory agencies scrutinise dose escalation strategies closely, expecting conservative starting doses, clear escalation rules, and robust safety oversight. As immunotherapies and advanced therapies introduce unique toxicity profiles, dose escalation methodologies continue evolving to improve patient safety and development efficiency.